Changes in MMP-2 and-9 activity and MMP-8 reactivity after amphotericin B induced synovitis and treatment with bufexamac
Changes in MMP-2 and-9 activity and MMP-8 reactivity after amphotericin B induced synovitis and treatment with bufexamac
复制标题
DOI：
10.1111/j.1439-0442.2006.00837.x
复制
发表时间：
2006-08-01
期刊：
影响因子：
--
通讯作者：
Tulamo, R. -M.
中科院分区：
文献类型：
--
作者：
Marttinen, P. H.;Raulo, S. M.;Tulamo, R. -M.
本文旨在评价诱导性关节炎对马滑液（SF）中基质金属蛋白酶（MMP）-2、-8和-9水平的急性影响。评估MMP-2和-9活性以及非甾体抗炎药（NSAID）丁非西酸在急性关节炎缓解期间的作用。在24匹标准马的右腕间关节中使用20 mg阿替霉素B作为单次关节内（IA）注射诱导无菌性关节炎。1周和2周后，用10、20或40 mg丁氨苯酸混悬液或无菌盐水溶液关节内给药马作为对照。在诱导前和每周一次采集SF样本，持续5周。通过明胶酶谱法或Western印迹法评价液体的MMP-2和MMP-9活性或MMP-8免疫反应性。腹腔注射阿朴霉素B后，MMP-8的免疫反应性、MMP-2和MMP-9的潜伏型和活性型均显著增加，其中活性型MMP-2的增加最多。MMP-9水平在2周内下降至诱导前水平，而MMP-2水平在5周后仍保持高水平。bufexamac治疗没有显着影响明胶溶解MMP的水平。结果表明，在马急性关节炎后，关节中存在MMP活性升高，持续数周，达到可促进软骨降解的程度，并且用NSAID bufexamac治疗不太可能影响。此外，分析MMP-9活性水平，特别是MMP-2活性的活性形式的水平可能对预测马关节炎的发生时间有价值。
The objective here was to evaluate the acute effects of induced arthritis on synovial fluid (SF) levels of matrix metalloproteinases (MMP) -2, -8 and -9 in horses. To evaluate MMP-2 and -9 activities and the effect of non-steroidal anti-inflammatory drug (NSAID) bufexamac during remission from acute arthritis. Aseptic arthritis was induced in 24 Standardbred horses using 20 mg of amphotericin B as a single intra-articular (IA) injection in the right intercarpal joint. After 1 week and 2 weeks, horses were treated intra-articularly with 10, 20, or 40 mg of bufexamac suspension or with sterile saline solution as control. SF was sampled prior to induction and at weekly intervals for 5 weeks. Fluids were evaluated for MMP-2 and MMP-9 activity by gelatin zymography or for MMP-8 immunoreactivity by Western Blotting. IA injection of amphotericin B consistently resulted in significant increase in the immunoreactivity of MMP-8 and activity of both the latent and the active forms of MMP-2 and -9, among which the active form of MMP-2 increased the most. MMP-9 levels declined to pre-induction levels within 2 weeks, whereas levels of MMP-2 remained still high after 5 weeks. Treatment with bufexamac did not significantly affect levels of gelatinolytic MMP. Results suggest that after acute arthritis of horses, elevated MMP activity is present in the joint, for several weeks, to a degree that could promote cartilage degradation, and treatment with the NSAID bufexamac is not likely to affect that. Furthermore, analysing levels of MMP-9 activity and especially levels of active forms of MMP-2 activity may be valuable to predict the time of occurrence of arthritis in horses.